Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roblin

Showing results (731-740 of 756) with videos related to

Pageof 76
Sort By:
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Rheumatology Advances in Practice|March 16, 2023
Management of systemic sclerosis: British Society for Rheumatology guideline scopeChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
BMJ Open|September 21, 2022
Cohort profile: pathways to care among people with disorders of sex development (DSD)Michael Goodman, Rami Yacoub, Darios Getahun, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosisChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summaryChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Pageof 76

Showing results (731-740 of 756) with videos related to

Sort By:
Pageof 76
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Rheumatology Advances in Practice|March 16, 2023
Management of systemic sclerosis: British Society for Rheumatology guideline scopeChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
BMJ Open|September 21, 2022
Cohort profile: pathways to care among people with disorders of sex development (DSD)Michael Goodman, Rami Yacoub, Darios Getahun, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosisChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summaryChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Pageof 76